Floatz logo

17 allylamino-17-demethoxygeldanamycin

Adult Mixed Cellularity Hodgkin Lymphoma

National Cancer Institute (NCI)Phase 2Dormant
B
57/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
42/ 100
Competitive Position
95/ 100

Competitive context

10 Active assets in the Adult Mixed Cellularity Hodgkin Lymphoma cohort.

Asset / SponsorPhaseRating
ETOPOSIDE
Northwestern University
Phase 3BB
Inno-206
National Cancer Institute (NCI)
Phase 3BB
FILGRASTIM
National Cancer Institute (NCI)
Phase 3BB
Ifosfamide
Northwestern University
Phase 3BB
BLEOMYCIN
City of Hope Medical Center
Phase 3BB

View all 33 →

Same molecule, other indications

17 allylamino-17-demethoxygeldanamycin is also rated in:

Adult Lymphocyte Depletion Hodgkin LymphomaDormant
B
Indicative ·
57 / 100
View asset →
von Hippel-Lindau diseaseDormant
B
Indicative ·
57 / 100
View asset →
nodular sclerosis classical Hodgkin lymphomaDormant
B
Indicative ·
57 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →